<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712244</url>
  </required_header>
  <id_info>
    <org_study_id>M07-014</org_study_id>
    <nct_id>NCT00712244</nct_id>
  </id_info>
  <brief_title>DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus</brief_title>
  <official_title>DisCoVisc Versus Competitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of the ability of DisCoVisc to that of other ophthalmic viscosurgical devices
      (OVDs) (DuoVisc, Healon5 or Amvisc PLUS) regarding endothelial protection and anterior
      chamber space maintenance during non-eventful cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Endothelial Cell Loss</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Percentage of corneal endothelial cells lost 1 month after surgery as compared to the number of corneal endothelial cells measured before surgery. Corneal endothelial cells are measured by counting the number of cells on an image taken by specular microscope.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Gain in Corneal Thickness.</measure>
    <time_frame>1 week and month after surgery</time_frame>
    <description>Percent Gain in Corneal Thickness between the assessment performed before surgery to that performed after surgery. This was assessed at both the 1 week and 1 month visit. Corneal thickness is measured in micrometers and is evaluated by Pachymetry. A negative number indicates a decrease in corneal thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous Signs - Corneal Edema</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Measured as the percentage of patient's eyes subjectively evaluated to have corneal edema at each of the following gradings: 0 - none; 1 - Mild, slight localized or generalized edema; 2 - Moderate, significant localized or generalized edema; 3 - Severe, advanced localized or generalized edema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous Signs - Aqueous Flare</measure>
    <time_frame>1 Day after Surgery</time_frame>
    <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Flare at each of the following gradings: 0 - None: No visible flare when compared to the normal eye, 1 - Mild: Flare visible against dark papillary background but not visible against iris background, 2 - Moderate: Flare is visible with the slit-lamp beam aimed onto the iris surface as well as teh dark papillary background, 3 - Severe: Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous Signs - Aqueous Cells</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Cells at each of the following gradings: 0 - None, 1 - 1 to 5 cells, 2 - 6 to 15 cells, 3 - 16 - 30 cells, 4 - &gt;30 cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Measure of intraocular pressure of a patient's eye via tonometry one day after surgery. Measured in mmHg. Normal intraocular pressure is between 10 mmHg and 20 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during anterior capsulotomy. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon Surgey - Anterior Dome Maintenance During Phacoemulsification</measure>
    <time_frame>Time of Surgery</time_frame>
    <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during phacoemulsification. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon Surgey - Anterior Dome Maintenance During Intraocular Lens (IOL) Insertion</measure>
    <time_frame>Time of Surgery</time_frame>
    <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during intraocular lens (IOL) insertion. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>DisCoVisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DuoVisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healon5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amvisc Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DisCoVisc</intervention_name>
    <description>Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.</description>
    <arm_group_label>DisCoVisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DuoVisc</intervention_name>
    <description>Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.</description>
    <arm_group_label>DuoVisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Healon5</intervention_name>
    <description>Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.</description>
    <arm_group_label>Healon5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amvisc Plus</intervention_name>
    <description>Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.</description>
    <arm_group_label>Amvisc Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  operable cataracts in at least one eye

        Exclusion Criteria:

          -  Endothelial Cell Count (ECC) ≤1500cells/mm2

          -  Intraocular Pressure (IOP) &gt; 21mm Hg

          -  previous ocular inflammation

          -  systemic or ocular conditions affecting corneal endothelium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Study Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <results_first_submitted>April 27, 2009</results_first_submitted>
  <results_first_submitted_qc>April 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2009</results_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rick Potvin</name_title>
    <organization>Alcon</organization>
  </responsible_party>
  <keyword>Discovisc</keyword>
  <keyword>Ophthalmic Viscosurgical Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were &gt;50 years old &amp; of any race &amp; gender. Subjects had operable cataracts in at least 1 eye, were able to provide informed consent, &amp; were free of systemic diseases affecting ocular health, especially those affecting endothelial cell counts. Eyes were free of ocular disease &amp; had no history of chronic/recurrent inflammatory eye disease.</recruitment_details>
      <pre_assignment_details>During the preoperative exam, subjects were examined to ensure they met the inclusion/exclusion criteria. Only subjects who signed an informed consent and qualified to be in the study by meeting all inclusion/exclusion criteria were enrolled. Group assignment was based on an Excel randomization scheme.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DISCOVISC</title>
          <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
        </group>
        <group group_id="P2">
          <title>DUOVISC</title>
          <description>DUOVISC® Viscoelastic system</description>
        </group>
        <group group_id="P3">
          <title>Healon5</title>
          <description>Healon5 Ophthalmic Viscosurgical Device</description>
        </group>
        <group group_id="P4">
          <title>Amvisc Plus</title>
          <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DISCOVISC</title>
          <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
        </group>
        <group group_id="B2">
          <title>DUOVISC</title>
          <description>DUOVISC® Viscoelastic system</description>
        </group>
        <group group_id="B3">
          <title>Healon5</title>
          <description>Healon5 Ophthalmic Viscosurgical Device</description>
        </group>
        <group group_id="B4">
          <title>Amvisc Plus</title>
          <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age data not available for 2 DisCoVisc subjects, 2 Duovisc subjects, and 1 AmVisc Plus subject.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender not available for 2 DisCoVisc subjects, 1 Duovisc subject, and 1 AmVisc Plus subject.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corneal Endothelial Cell Loss</title>
        <description>Percentage of corneal endothelial cells lost 1 month after surgery as compared to the number of corneal endothelial cells measured before surgery. Corneal endothelial cells are measured by counting the number of cells on an image taken by specular microscope.</description>
        <time_frame>1 month after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Endothelial Cell Loss</title>
          <description>Percentage of corneal endothelial cells lost 1 month after surgery as compared to the number of corneal endothelial cells measured before surgery. Corneal endothelial cells are measured by counting the number of cells on an image taken by specular microscope.</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="5.99"/>
                    <measurement group_id="O2" value="1.18" spread="11.18"/>
                    <measurement group_id="O3" value="4.72" spread="7.23"/>
                    <measurement group_id="O4" value="6.30" spread="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Gain in Corneal Thickness.</title>
        <description>Percent Gain in Corneal Thickness between the assessment performed before surgery to that performed after surgery. This was assessed at both the 1 week and 1 month visit. Corneal thickness is measured in micrometers and is evaluated by Pachymetry. A negative number indicates a decrease in corneal thickness.</description>
        <time_frame>1 week and month after surgery</time_frame>
        <population>Participants analyzed for Baseline to 1 week: 29 DisCovisc, 28 DuoVisc, 26 Healon5, 26 Amvisc Plus.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Gain in Corneal Thickness.</title>
          <description>Percent Gain in Corneal Thickness between the assessment performed before surgery to that performed after surgery. This was assessed at both the 1 week and 1 month visit. Corneal thickness is measured in micrometers and is evaluated by Pachymetry. A negative number indicates a decrease in corneal thickness.</description>
          <population>Participants analyzed for Baseline to 1 week: 29 DisCovisc, 28 DuoVisc, 26 Healon5, 26 Amvisc Plus.</population>
          <units>Percent Gain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Surgery to 1 Week after Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="16.45"/>
                    <measurement group_id="O2" value="7.02" spread="12.06"/>
                    <measurement group_id="O3" value="9.92" spread="15.29"/>
                    <measurement group_id="O4" value="5.06" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Surgery to 1 Month after Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="11.79"/>
                    <measurement group_id="O2" value="-1.06" spread="25.38"/>
                    <measurement group_id="O3" value="1.98" spread="10.57"/>
                    <measurement group_id="O4" value="-9.11" spread="22.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Signs - Corneal Edema</title>
        <description>Measured as the percentage of patient's eyes subjectively evaluated to have corneal edema at each of the following gradings: 0 - none; 1 - Mild, slight localized or generalized edema; 2 - Moderate, significant localized or generalized edema; 3 - Severe, advanced localized or generalized edema.</description>
        <time_frame>1 day after surgery</time_frame>
        <population>This data was collected for all subjects attending the visit one day after surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Signs - Corneal Edema</title>
          <description>Measured as the percentage of patient's eyes subjectively evaluated to have corneal edema at each of the following gradings: 0 - none; 1 - Mild, slight localized or generalized edema; 2 - Moderate, significant localized or generalized edema; 3 - Severe, advanced localized or generalized edema.</description>
          <population>This data was collected for all subjects attending the visit one day after surgery.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.97"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="57.69"/>
                    <measurement group_id="O4" value="65.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.59"/>
                    <measurement group_id="O2" value="21.43"/>
                    <measurement group_id="O3" value="34.62"/>
                    <measurement group_id="O4" value="34.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45"/>
                    <measurement group_id="O2" value="3.57"/>
                    <measurement group_id="O3" value="7.69"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Signs - Aqueous Flare</title>
        <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Flare at each of the following gradings: 0 - None: No visible flare when compared to the normal eye, 1 - Mild: Flare visible against dark papillary background but not visible against iris background, 2 - Moderate: Flare is visible with the slit-lamp beam aimed onto the iris surface as well as teh dark papillary background, 3 - Severe: Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.</description>
        <time_frame>1 Day after Surgery</time_frame>
        <population>This data was collected for all subjects attending the visit one day after surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Signs - Aqueous Flare</title>
          <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Flare at each of the following gradings: 0 - None: No visible flare when compared to the normal eye, 1 - Mild: Flare visible against dark papillary background but not visible against iris background, 2 - Moderate: Flare is visible with the slit-lamp beam aimed onto the iris surface as well as teh dark papillary background, 3 - Severe: Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.</description>
          <population>This data was collected for all subjects attending the visit one day after surgery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.69"/>
                    <measurement group_id="O2" value="39.29"/>
                    <measurement group_id="O3" value="26.92"/>
                    <measurement group_id="O4" value="46.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.86"/>
                    <measurement group_id="O2" value="53.57"/>
                    <measurement group_id="O3" value="65.38"/>
                    <measurement group_id="O4" value="53.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="7.69"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Signs - Aqueous Cells</title>
        <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Cells at each of the following gradings: 0 - None, 1 - 1 to 5 cells, 2 - 6 to 15 cells, 3 - 16 - 30 cells, 4 - &gt;30 cells.</description>
        <time_frame>1 day after surgery</time_frame>
        <population>This data was collected for all subjects attending the visit one day after surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Signs - Aqueous Cells</title>
          <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Cells at each of the following gradings: 0 - None, 1 - 1 to 5 cells, 2 - 6 to 15 cells, 3 - 16 - 30 cells, 4 - &gt;30 cells.</description>
          <population>This data was collected for all subjects attending the visit one day after surgery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="14.29"/>
                    <measurement group_id="O3" value="7.69"/>
                    <measurement group_id="O4" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.52"/>
                    <measurement group_id="O2" value="46.43"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="65.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.14"/>
                    <measurement group_id="O2" value="32.14"/>
                    <measurement group_id="O3" value="38.46"/>
                    <measurement group_id="O4" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="3.85"/>
                    <measurement group_id="O4" value="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>Measure of intraocular pressure of a patient's eye via tonometry one day after surgery. Measured in mmHg. Normal intraocular pressure is between 10 mmHg and 20 mmHg.</description>
        <time_frame>1 day after surgery</time_frame>
        <population>This data was collected on all subjects attending the visit one day after surgery with the exception of 3 DisCoVisc subjects, 4 DuoVisc subjects, 2 Healon5 subjects, and 1 AmVisc Plus subject.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>Measure of intraocular pressure of a patient's eye via tonometry one day after surgery. Measured in mmHg. Normal intraocular pressure is between 10 mmHg and 20 mmHg.</description>
          <population>This data was collected on all subjects attending the visit one day after surgery with the exception of 3 DisCoVisc subjects, 4 DuoVisc subjects, 2 Healon5 subjects, and 1 AmVisc Plus subject.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.58" spread="8.42"/>
                    <measurement group_id="O2" value="19.48" spread="4.6"/>
                    <measurement group_id="O3" value="20.72" spread="6.61"/>
                    <measurement group_id="O4" value="18.65" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgeon Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy</title>
        <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during anterior capsulotomy. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
        <time_frame>Time of surgery</time_frame>
        <population>This data was collected on all subjects undergoing surgery with the exception of 1 DuoVisc subject.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Surgeon Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy</title>
          <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during anterior capsulotomy. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
          <population>This data was collected on all subjects undergoing surgery with the exception of 1 DuoVisc subject.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shallow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45"/>
                    <measurement group_id="O2" value="3.57"/>
                    <measurement group_id="O3" value="22.22"/>
                    <measurement group_id="O4" value="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Space Adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="48.15"/>
                    <measurement group_id="O4" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Chamber Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.55"/>
                    <measurement group_id="O2" value="89.29"/>
                    <measurement group_id="O3" value="29.63"/>
                    <measurement group_id="O4" value="25.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgeon Surgey - Anterior Dome Maintenance During Phacoemulsification</title>
        <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during phacoemulsification. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
        <time_frame>Time of Surgery</time_frame>
        <population>This data was collected on all subjects undergoing surgery with the exception of 1 DuoVisc subject.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Surgeon Surgey - Anterior Dome Maintenance During Phacoemulsification</title>
          <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during phacoemulsification. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
          <population>This data was collected on all subjects undergoing surgery with the exception of 1 DuoVisc subject.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shallow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11.11"/>
                    <measurement group_id="O4" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Space Adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.57"/>
                    <measurement group_id="O3" value="51.85"/>
                    <measurement group_id="O4" value="48.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Chamber Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96.43"/>
                    <measurement group_id="O3" value="37.04"/>
                    <measurement group_id="O4" value="48.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgeon Surgey - Anterior Dome Maintenance During Intraocular Lens (IOL) Insertion</title>
        <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during intraocular lens (IOL) insertion. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
        <time_frame>Time of Surgery</time_frame>
        <population>This data was collected on all subjects undergoing surgery with the exception of 1 DuoVisc subject.</population>
        <group_list>
          <group group_id="O1">
            <title>DISCOVISC</title>
            <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
          </group>
          <group group_id="O2">
            <title>DUOVISC</title>
            <description>DUOVISC® Viscoelastic system</description>
          </group>
          <group group_id="O3">
            <title>Healon5</title>
            <description>Healon5 Ophthalmic Viscosurgical Device</description>
          </group>
          <group group_id="O4">
            <title>Amvisc Plus</title>
            <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
          </group>
        </group_list>
        <measure>
          <title>Surgeon Surgey - Anterior Dome Maintenance During Intraocular Lens (IOL) Insertion</title>
          <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a subject's eye during intraocular lens (IOL) insertion. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
          <population>This data was collected on all subjects undergoing surgery with the exception of 1 DuoVisc subject.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shallow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="40.74"/>
                    <measurement group_id="O4" value="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Space Adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.14"/>
                    <measurement group_id="O3" value="25.93"/>
                    <measurement group_id="O4" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Chamber Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="92.86"/>
                    <measurement group_id="O3" value="33.33"/>
                    <measurement group_id="O4" value="48.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There were no adverse events reported for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>DISCOVISC</title>
          <description>DISCOVISC® Ophthalmic Viscosurgical Device (OVD)</description>
        </group>
        <group group_id="E2">
          <title>DUOVISC</title>
          <description>DUOVISC® Viscoelastic system</description>
        </group>
        <group group_id="E3">
          <title>Healon5</title>
          <description>Healon5 Ophthalmic Viscosurgical Device</description>
        </group>
        <group group_id="E4">
          <title>Amvisc Plus</title>
          <description>Amvisc Plus Ophthalmic Viscosurgical Device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

